SCHEMBL2067775

SCHEMBL2067775

c1csc(Nc2nccc3sccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.43
ALDH1A1 P00352 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
CSF1R P07333 1/20 0.39
LTK P29376 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
CDK7 P50613 1/20 0.39
CDK9 P50750 1/20 0.39
RPS6KA3 P51812 1/20 0.39
CDK5 Q00535 1/20 0.39
PTK2 Q05397 1/20 0.39
CAMK1D Q8IU85 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
ALK Q9UM73 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
HTR2C P28335 1/20 0.39
GCK P35557 1/20 0.39
MEN1 O00255 2/20 0.38
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20265384 0.77 HTR2C (0.41) ALDH1A1TDP1CSF1RLTKMAPK8
SCHEMBL20278247 0.77 HTR2C (0.41) ALDH1A1TDP1HTR2CMEN1GAA
SCHEMBL5334309 0.76 SRC (0.48) GRM4HTR2CMEN1KMT2AKDM4E
SCHEMBL16245731 0.76 KMT2A (0.44) TDP1HTR2CMEN1GAAKMT2A
SCHEMBL6704628 0.75 KDR (0.49)
SCHEMBL5311682 0.74 CSNK2A2 (0.41) ALDH1A1HTR2CMEN1GAAKMT2A
SCHEMBL2066250 0.72 MYC (0.38) HTR2C
SCHEMBL30737928 0.72 GRM4 (0.42) GRM4HTR2CMEN1KMT2ANPC1
SCHEMBL1369210 0.72 ALDH1A1 (0.50) GRM4ALDH1A1TDP1MEN1GAA
SCHEMBL5331600 0.71 EPAS1 (0.52) LTKMAPK8CDK7CLK4DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099794-B1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
EP-2099794-B1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
CN-101652363-B Thiazolyl compounds useful as kinase inhibitors BRISTOL MYERS SQUIBB CO 2013-04-17 CN disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
CN-101652363-A Thiazolyl compounds as kinase inhibitor SQUIBB BRISTOL MYERS CO US 2010-02-17 CN disclosed
WO-2008079873-A2 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS ERBB2, TEC, TTBK1 GRM4 3140/4885ALDH1A1 1870/4885TDP1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.